Skip to main content
SpringerLink
Log in

Disease activity-guided TNFi therapy cost saving for RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Dose REduction Strategy of Subcutaneous TNF inhibitors

Reference

  • Kievit W, et al. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases : 13 Jan 2016. Available from: URL: http://doi.org/10.1136/annrheumdis-2015-208317

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Disease activity-guided TNFi therapy cost saving for RA. PharmacoEcon Outcomes News 745, 15 (2016). https://doi.org/10.1007/s40274-016-2756-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2756-3

Search

Navigation